​

scPharmaceuticals (SCPH) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

SCPH Stock Forecast

scPharmaceuticals stock forecast is as follows: an average price target of $13.00 (represents a 283.48% upside from SCPH’s last price of $3.39) and a rating consensus of 'Buy', based on 3 wall street analysts offering a 1-year stock forecast.

SCPH Price Target

The average price target for scPharmaceuticals (SCPH) is $13.00 based on 1-year price targets from 3 Wall Street analysts in the past 3 months, with a price target range of $13.00 to $13.00. This represents a potential 283.48% upside from SCPH's last price of $3.39.

SCPH Analyst Ratings

Buy

According to 3 Wall Street analysts, scPharmaceuticals's rating consensus is 'Buy'. The analyst rating breakdown for SCPH stock is 0 'Strong Buy' (0.00%), 3 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

scPharmaceuticals Price Target by Analyst

DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Dec 02, 2024Glen SantangeloJefferies$13.00$3.81241.21%283.48%

The latest scPharmaceuticals stock forecast, released on Dec 02, 2024 by Glen Santangelo from Jefferies, set a price target of $13.00, which represents a 241.21% increase from the stock price at the time of the forecast ($3.81), and a 283.48% increase from SCPH last price ($3.39).

scPharmaceuticals Price Target by Period

1M3M12M
# Anlaysts111
Avg Price Target$13.00$13.00$13.00
Last Closing Price$3.39$3.39$3.39
Upside/Downside283.48%283.48%283.48%

In the current month, the average price target of scPharmaceuticals stock is $13.00, according to 1 Wall Street analyst offering twelve months forecast. The average price target represents a 283.48% increase as opposed to scPharmaceuticals's last price of $3.39. This month's average price target is down 0.00% compared to last quarter, and down 0.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

DateCompanyPrevious RatingNew RatingRating Change
Dec 02, 2024JefferiesBuyBuyHold
Oct 23, 2024Cowen & Co.BuyBuyHold
Oct 11, 2022SVB LeerinkOutperformUpgrade

scPharmaceuticals's last stock rating was published by Jefferies on Dec 02, 2024. The company gave SCPH a "Buy" rating, the same as its previous rate.

scPharmaceuticals Financial Forecast

scPharmaceuticals Revenue Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23
Revenue--------$6.10M$3.80M$1.64M$2.06M
Avg Forecast$27.90M$21.70M$18.23M$14.43M$12.18M$10.81M$7.97M$5.98M$5.52M$3.40M$1.45M$1.75M
High Forecast$29.02M$22.57M$18.97M$15.01M$12.41M$11.24M$7.97M$5.98M$5.74M$3.40M$1.50M$1.82M
Low Forecast$26.57M$20.66M$17.36M$13.74M$12.04M$10.29M$7.97M$5.98M$5.26M$3.40M$1.38M$1.67M
# Analysts111242113111
Surprise %--------1.10%1.12%1.13%1.18%

scPharmaceuticals's average Quarter revenue forecast for Mar 24 based on 1 analysts is $5.98M, with a low forecast of $5.98M, and a high forecast of $5.98M. SCPH's average Quarter revenue forecast represents a -1.95% decrease compared to the company's last Quarter revenue of $6.10M (Dec 23).

scPharmaceuticals EBITDA Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23
# Analysts111242113111
EBITDA--------$-15.12M$-14.84M$-13.75M$-9.25M
Avg Forecast$16.74M$13.02M$10.94M$8.66M$7.31M$6.49M$4.78M$3.59M$3.31M$2.04M$867.03K$1.05M
High Forecast$17.41M$13.54M$11.38M$9.01M$7.44M$6.75M$4.78M$3.59M$3.45M$2.04M$901.86K$1.09M
Low Forecast$15.94M$12.40M$10.42M$8.25M$7.22M$6.18M$4.78M$3.59M$3.15M$2.04M$825.67K$1.00M
Surprise %---------4.56%-7.28%-15.85%-8.79%

undefined analysts predict SCPH's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than scPharmaceuticals's previous annual EBITDA (undefined) of $NaN.

scPharmaceuticals Net Income Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23
# Analysts111242113111
Net Income--------$-13.81M$-15.63M$-14.15M$-12.83M
Avg Forecast$-6.83M$-10.40M$-11.95M$-13.66M$-17.54M$-13.89M$-19.48M$-20.33M$-19.50M$-16.99M$-17.43M$-16.85M
High Forecast$-6.41M$-9.75M$-11.21M$-12.81M$-11.40M$-13.03M$-18.27M$-19.07M$-14.51M$-15.94M$-16.35M$-15.81M
Low Forecast$-7.19M$-10.94M$-12.57M$-14.37M$-21.49M$-14.62M$-20.49M$-21.39M$-23.58M$-17.88M$-18.34M$-17.73M
Surprise %--------0.71%0.92%0.81%0.76%

scPharmaceuticals's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. SCPH's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

scPharmaceuticals SG&A Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23
# Analysts111242113111
SG&A--------$16.24M$14.13M$12.10M$10.90M
Avg Forecast$44.23M$34.40M$28.90M$22.88M$19.30M$17.13M$12.63M$9.48M$8.75M$5.38M$2.29M$2.78M
High Forecast$46.00M$35.78M$30.07M$23.80M$19.67M$17.82M$12.63M$9.48M$9.10M$5.38M$2.38M$2.89M
Low Forecast$42.12M$32.76M$27.53M$21.79M$19.08M$16.32M$12.63M$9.48M$8.33M$5.38M$2.18M$2.65M
Surprise %--------1.86%2.63%5.28%3.92%

scPharmaceuticals's average Quarter SG&A projection for Mar 24 is $9.48M, based on 1 Wall Street analysts, with a range of $9.48M to $9.48M. The forecast indicates a -41.66% fall compared to SCPH last annual SG&A of $16.24M (Dec 23).

scPharmaceuticals EPS Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23
# Analysts111242113111
EPS--------$-0.36$-0.00$-0.00$-0.34
Avg Forecast$-0.15$-0.22$-0.26$-0.29$-0.38$-0.30$-0.42$-0.44$-0.42$-0.36$-0.37$-0.36
High Forecast$-0.14$-0.21$-0.24$-0.28$-0.24$-0.28$-0.39$-0.41$-0.31$-0.34$-0.35$-0.34
Low Forecast$-0.15$-0.23$-0.27$-0.31$-0.46$-0.31$-0.44$-0.46$-0.51$-0.38$-0.39$-0.38
Surprise %--------0.86%0.00%0.00%0.94%

According to undefined Wall Street analysts, scPharmaceuticals's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to SCPH previous annual EPS of $NaN (undefined).

scPharmaceuticals Peer Comparison by Price Target

TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
MISTMilestone Pharmaceuticals$1.82$10.00449.45%Buy
SCPHscPharmaceuticals$3.25$13.00300.00%Buy
LYRALyra Therapeutics$0.18$0.50177.78%Hold
DMACDiaMedica Therapeutics$5.20$8.5063.46%Buy
IOVAIovance Biotherapeutics$7.81$12.4058.77%Buy
MCRBSeres Therapeutics$0.88$1.2542.05%Buy
CNTACentessa Pharmaceuticals$17.60$23.2532.10%Buy
MNPRMonopar Therapeutics$30.68$29.50-3.85%Buy

SCPH Forecast FAQ

Is scPharmaceuticals a good buy?

Yes, according to 3 Wall Street analysts, scPharmaceuticals (SCPH) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 3 'Buy' recommendations, accounting for 100.00% of SCPH's total ratings.

What is SCPH's price target?

scPharmaceuticals (SCPH) average price target is $13 with a range of $13 to $13, implying a 283.48% from its last price of $3.39. The data is based on 3 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will scPharmaceuticals stock go up soon?

According to Wall Street analysts' prediction for SCPH stock, the company can go up by 283.48% (from the last price of $3.39 to the average price target of $13), up by 283.48% based on the highest stock price target, and up by 283.48% based on the lowest stock price target.

Can scPharmaceuticals stock reach $5?

SCPH's average twelve months analyst stock price target of $13 supports the claim that scPharmaceuticals can reach $5 in the near future.

What is scPharmaceuticals's current price target trend?

1 Wall Street analyst forecast a $13 price target for scPharmaceuticals (SCPH) this month, up 283.48% from its last price of $3.39. Compared to the last 3 and 12 months, the average price target increased by 283.48% and increased by 283.48%, respectively.

What are scPharmaceuticals's analysts' financial forecasts?

scPharmaceuticals's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $36.93M (high $37.6M, low $36.28M), average EBITDA is $22.16M (high $22.56M, low $21.77M), average net income is $-71.237M (high $-61.768M, low $-77.987M), average SG&A $58.55M (high $59.6M, low $57.5M), and average EPS is $-1.53 (high $-1.327, low $-1.675). SCPH's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $82.27M (high $85.57M, low $78.34M), average EBITDA is $49.36M (high $51.34M, low $47.01M), average net income is $-42.834M (high $-40.177M, low $-45.07M), average SG&A $130.41M (high $135.65M, low $124.19M), and average EPS is $-0.92 (high $-0.863, low $-0.968).

Did the SCPH's actual financial results beat the analysts' financial forecasts?

Based on scPharmaceuticals's last annual report (Dec 2023), the company's revenue was $13.59M, beating the average analysts forecast of $12.12M by 12.20%. Apple's EBITDA was $-55.396M, missing the average prediction of $7.27M by -862.07%. The company's net income was $-54.81M, missing the average estimation of $-70.782M by -22.57%. Apple's SG&A was $53.37M, beating the average forecast of $19.21M by 177.88%. Lastly, the company's EPS was $-0.0014, missing the average prediction of $-1.52 by -99.91%. In terms of the last quarterly report (Dec 2023), scPharmaceuticals's revenue was $6.1M, beating the average analysts' forecast of $5.52M by 10.42%. The company's EBITDA was $-15.117M, missing the average prediction of $3.31M by -556.36%. scPharmaceuticals's net income was $-13.812M, missing the average estimation of $-19.5M by -29.17%. The company's SG&A was $16.24M, beating the average forecast of $8.75M by 85.58%. Lastly, the company's EPS was $-0.36, missing the average prediction of $-0.419 by -14.04%